[{"orgOrder":0,"company":"Duchesnay","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Duchesnay \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Inapplicable"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Steroid","year":"2020","type":"Partnership","leadProduct":"Ospemifene","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duchesnay \/ Plushcare","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Plushcare"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Population Council","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Duchesnay \/ Population Council","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Population Council"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dequalinium Chloride","moa":"Enzymes","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Tablet","sponsorNew":"Duchesnay \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Inapplicable"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Health Decisions","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxylamine","moa":"Histamine H1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duchesnay \/ Health Decisions","highestDevelopmentStatusID":"11","companyTruncated":"Duchesnay \/ Health Decisions"}]

Find Clinical Drug Pipeline Developments & Deals by Duchesnay

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : PHEBURANE® (sodium phenylbutyrate) is indicated adjunctive therapy to standard of care, which includes dietary management, for chronic management of adult and pediatric patients with UCDs.

                          Product Name : Pheburane

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 19, 2022

                          Lead Product(s) : Sodium Phenylbutyrate

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Vablys® (dequalinium chloride vaginal tablets), is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women under 55 years of age.

                          Product Name : Vablys

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 21, 2022

                          Lead Product(s) : Dequalinium Chloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 21, 2022

                          Lead Product(s) : Doxylamine

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : Health Decisions

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : As part of the agreement, Duchesnay will explore opportunities to register ANNOVERA with local regulatory agencies in these regions and will invest in the Population Council’s research activities to develop new innovative contraceptive products.

                          Product Name : Annovera

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          November 30, 2020

                          Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Population Council

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of the...

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          May 19, 2020

                          Lead Product(s) : Ospemifene

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Plushcare

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : PregVit

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          November 25, 2014

                          Lead Product(s) : Folic Acid

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Recipient : The Hospital for Sick Children

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : PregVit

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          November 24, 2014

                          Lead Product(s) : Folic Acid

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Recipient : The Hospital for Sick Children

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 27, 2014

                          Lead Product(s) : Doxylamine

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Sponsor : Premier Research Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank